Become a member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Omni Shoreham Hotel

Dec 05, 2016 1:00 PM - Dec 06, 2016 5:00 PM

2500 Calvert Street NW, , Washington, DC 20008 , USA

Advancing the Science of Study Endpoints

Examine global strategies for selecting study endpoints and the impact of endpoints during the analysis of clinical evidence for various types of drug approval processes.

Back to Agenda

Session 7: Clinical Trial Grade Wearables – The Current State of the Science

Session Chair(s)

Keith Wenzel

Volunteer

DIA Study Endpoints Community, United States

A moderated discussion including audience questions and participation on the valid use of wearables in clinical trials, focusing on identification of valid devices and validation of clinical endpoints derived from wearable data.

Speaker(s)

Session Co-Chair

Bill Byrom, PhD

Signant Health , United Kingdom

Vice President, Product Intelligence and Positioning; Principal, eCOA Science

Moderator

Chad Gwaltney, PhD

Gwaltney Consulting, United States

President

Panelist

Elektra Papadopoulos, MD, MPH

AbbVie, United States

Director, Patient Experience Data and Strategy

Panelist

Robert Alan Vigersky, MD, FACP

Medtronic, United States

Medical Director

Panelist

Robert DiCicco, PharmD

TransCelerate Biopharma Inc., United States

Vice President, Portfolio Management

Have an account?

Advancing the Science of Study Endpoints

Session 7: Clinical Trial Grade Wearables – The Current State of the Science

Session Chair(s)

Keith Wenzel

Speaker(s)

Session Co-Chair

Moderator

Panelist

Panelist

Panelist

Be informed and stay engaged.